People · Operator

LEAF HUANG

Named in public records as an officer, director or promoter · active 2008–2017 · Pharmaceuticals, Biotechnology

2
Companies
3
Filings
$13.2M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Lipella Pharmaceuticals Inc.PharmaceuticalsSeed$8.2M$9.6M2008
OncoTrap, Inc.BiotechnologySeries A$5.0M$180.8M2017
Operator network

LEAF HUANG at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Daniel Cohen · 15 companies · 1 sharedDaniel CohenJonathan Kaufman · 3 companies · 1 sharedJonathan KaufmanDAVID BATTLEMAN · 2 companies · 1 sharedDAVID BATTLEMANTHOMAS PETZINGER, JR. · 2 companies · 1 sharedTHOMAS PETZINGER,…BERNARD TOKARCZYK · 1 companies · 1 sharedBERNARD TOKARCZYKByong Kim · 1 companies · 1 sharedByong KimDouglas Johnston · 1 companies · 1 sharedDouglas JohnstonLori Birder · 1 companies · 1 sharedLori BirderMICHAEL CHANCELLOR · 1 companies · 1 sharedMICHAEL CHANCELLORNaoki Yoshimura · 1 companies · 1 sharedNaoki YoshimuraPRADEEP TYAGI · 1 companies · 1 sharedPRADEEP TYAGIRyan Pruchnic · 1 companies · 1 sharedRyan PruchnicRihe Liu · 1 companies · 1 sharedRihe LiuLipella Pharmaceuticals Inc. · $8.2M raisedLipella Pharmaceutica…OncoTrap, Inc. · $5.0M raisedOncoTrap, Inc.LEAF HUANGLH
LEAF HUANG Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside LEAF HUANG on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Daniel Cohen115
Jonathan Kaufman13
THOMAS PETZINGER, JR.12
DAVID BATTLEMAN12
Rihe Liu11
PRADEEP TYAGI11
BERNARD TOKARCZYK11
Lori Birder11
Byong Kim11
Douglas Johnston11
Ryan Pruchnic11
Naoki Yoshimura11
MICHAEL CHANCELLOR11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.